The FDA has granted fast-track designation to GSK's bepirovirsen, an antisense drug, for chronic hepatitis B (CHB) treatment, expediting its review process.
Roche has entered into a $200 million upfront deal with Dicerna Pharmaceuticals for a gene-silencing drug aimed at treating hepatitis B virus (HBV) infections, with potential payments reaching up to $1.47 billion based on the drug's success. The drug, DCR-HBVS, currently in phase 1 testing, targets genes used by the virus to enter liver cells, offering hope for a functional cure by suppressing the virus below detectable levels.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.